Technology
Health
Pharmaceutical

Akcea Therapeutics

$27.34
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.51 (-1.83%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AKCA and other stocks, options, ETFs, and crypto commission-free!

About

Akcea Therapeutics, Inc. engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. Read More It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA.

Employees
248
Headquarters
Boston, Massachusetts
Founded
2014
Market Cap
2.49B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
293.07K
High Today
$28.92
Low Today
$26.75
Open Price
$28.64
Volume
94.61K
52 Week High
$40.75
52 Week Low
$17.74

Collections

Technology
Health
Pharmaceutical
Therapy
2017 IPO
US
North America
Female CEOs

News

MarketBeatMar 9

Stock Price, News, & Analysis for Akcea Therapeutics

Akcea Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Ph...

17
Simply Wall StMar 1

Will Akcea Therapeutics, Inc.’s (NASDAQ:AKCA) Earnings Grow Over The Next Few Years?

Akcea Therapeutics, Inc.’s (NASDAQ:AKCA) most recent earnings announcement in December 2018 indicated company earnings became less negative compared to the previous year’s level as a result of recent tailwinds Investors may find it useful to understand how market analysts predict Akcea Therapeutics’s earnings growth trajectory over the next couple of years and whether the future looks brighter. I will be using net income excluding extraordinary items in order to exclude one-off volatility which I am not int...

12
The Motley FoolFeb 26

Akcea Therapeutics, Inc. (AKCA) Q4 2018 Earnings Conference Call Transcript

Akcea Therapeutics, Inc. (NASDAQ:AKCA) Q4 2018 Earnings Conference Call , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon, and welcome to the Akcea Therapeutics Fourth Quarter and Year-end 2018 Conference Call. As a reminder, this call is being recorded. I will now turn the call over to Kathleen Gallagher, Akcea's Vice President of Corporate Communications and Investor Relations. Ms. Gallagher, please begin. Kathleen Gallag...

52

Earnings

-$1.24
-$0.89
-$0.53
-$0.18
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 2, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.